# A Study of LY3841136 in Overweight and Obese Participants

> **NCT06345066** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 96 (actual)

## Conditions studied

- Obesity
- Overweight

## Interventions

- **DRUG:** Tirzepatide
- **DRUG:** LY3841136
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06345066
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-03
- **Primary completion:** 2025-09-29
- **Final completion:** 2025-09-29
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2025-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06345066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06345066, "A Study of LY3841136 in Overweight and Obese Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06345066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*